XHEL
REG1V
Market cap409mUSD
Aug 03, Last price
12.74EUR
1D
4.26%
1Q
-5.63%
Jan 2017
25.39%
IPO
2,148.22%
Name
Revenio Group Oyj
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Revenio Group Oyj operates as a healthcare technology company, specializing in the development, production, and global distribution of advanced ophthalmic diagnostic instruments and medical devices. These innovations are engineered to aid in the identification of various eye conditions, including glaucoma, macular degeneration, diabetic retinopathy, and cataracts, serving clientele in Finland, throughout Europe, and worldwide. Its extensive product portfolio includes the iCare IC100 and IC200 tonometers, along with the iCare HOME device for personal eye pressure monitoring. Furthermore, the company provides sophisticated imaging technologies such as the iCare EIDON AF for confocal retinal imaging, DRSplus for screening diabetic retinopathy, the iCare MAIA microperimeter for precise visual field measurements, and iCare COMPASS, which facilitates fundus perimetry using true-color retinal images. Beyond hardware, Revenio also offers Oculo, a comprehensive eye care software platform that seamlessly integrates clinical communication, telehealth functionalities, remote patient monitoring, and robust data analytics. Established in 2001, Revenio Group Oyj is based in Vantaa, Finland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||